CTI BioPharma (CTIC) – Major News
-
CTI BioPharma (CTIC) Acquired by Sobi for $9.10/sh or $1.7B Cash
-
CTI BioPharma (CTIC) Misses Q2 EPS by 2c
-
CTI BioPharma (CTIC) Misses Q1 EPS by 4c
-
CTI BioPharma (CTIC) Misses Q1 EPS by 1c
-
CTI BioPharma (CTIC) Misses Q4 EPS by 4c
-
CTI BioPharma (CTIC) Reports In-Line Q3 EPS
-
CTI BioPharma (CTIC) Phase III Trial Evaluating PFS of PIXUVRI Combined with Rituximab in Patients with Aggressive B-cell NHL Did Not Meet Primary Endpoint
-
CTI BioPharma (CTIC) Tops Q1 EPS by 2c
-
CTI BioPharma (CTIC) Misses Q4 EPS by 4c
-
CTI BioPharma (CTIC) Reports Q3 Loss of $0.28
-
CTI BioPharma (CTIC) Reports Q2 EPS of $0.03
-
CTI BioPharma (CTIC) Misses Q1 EPS by 1c
-
CTI BioPharma (CTIC) Reports Q4 Loss of $0.23
-
CTI BioPharma (CTIC) Names Adam Craig as President and CEO
-
CTI BioPharma (CTIC) CEO Bianco to Retire
-
CTI BioPharma's (CTIC) Pacritinib Placed on Full Clinical Hold; NDA Withdrawn
-
FDA Places Partial Clinical Hold on CTI BioPharma's (CTIC) Pacritinib IND
-
CTI BioPharma (CTIC) Misses Q3 EPS by 7c
-
CTI BioPharma (CTIC) Completes pre-NDA Meeting on Pacritinib; Updates on PERSIST-1
-
CTI BioPharma (CTIC) Misses Q2 EPS by 9c
-
CTI BioPharma (CTIC) Misses Q1 EPS by 2c
-
CTI BioPharma (CTIC) Misses Q4 EPS by 9c, Offers Guidance
-
CTI BioPharma (CTIC), Baxter (BAX) Report PERSIST-1 Met Primary Enpoint
-
CTI BioPharma (CTIC) Sees Prelim. FY14 Revs at $60M; Guides FY15 Revenue Above Views
-
CTI BioPharma (CTIC) Pacritinib Granted FDA Fast Track Status
-
Cell Therapeutics Inc. (CTIC) Reports Q1 Loss of $0.20
-
Cell Therapeutics Inc. (CTIC) Posts Surprise Q4 Profit of 8c/Share
-
Baxter (BAX), Cell Therapeutics (CTIC) Enter Exclusive Pacritinib Pact
-
Cell Therapeutics Inc. (CTIC) Reports In-Line Q4 Loss of $0.20/Sh
-
Cell Therapeutics Inc. (CTIC) Narrows Q3 Loss to 38c/Share
-
Cell Therapeutics Inc. (CTIC) Widens Q2 Loss to 28c/Share
-
Cell Therapeutics (CTIC) Posts Narrower Q1 Loss of 9c/Share
-
Cell Therapeutics Inc. (CTIC) Posts Q4 Loss of 9c/Share
-
Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
-
Cell Therapeutics, Inc. (CTIC) Narrows Q2 Loss
-
Cell Therapeutics, Inc. (CTIC) Misses Q4 EPS by 4c
-
Cell Therapeutics, Inc. (CTIC) Posts Mixed Q2 Earnings Results
-
Cell Therapeutics (CTIC) Provides Update on FDA Advisory Committee Meeting on Pixantrone
-
Cell Therapeutics (CTIC) Given April 23 PDUFA Date by FDA for Pixantron
Back to CTIC Stock Lookup